Although there are limited reported findings on syndecan-3 in BC, existing evidence has suggested that syndecan-3 is linked to hypoxia-associated and glycolytic gene signatures and interacts with the tissue factor pathway inhibitor (TFPI), affecting tumour-associated coagulation [43,44,45]. Here, SDC3 is linked to breast cancer.